---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000067"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:31:14.550615+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech reports Q2 2023 net loss $33.2M; VYJUVEK launch yields 121 patient start forms

## Summary
- VYJUVEK approved May 19; 121 Patient Start Forms submitted in first six weeks of launch.
- Cash, cash equivalents and investments $505.9M as of June 30, 2023.
- Net loss $33.2M ($1.25 per share) vs $28.1M ($1.10 per share) in Q2 2022.
- First CF patient dosed with KB407 in Phase 1 trial; KB707 IND accepted with Fast Track designation.
- Positive coverage from UnitedHealthcare and other national/regional health plans for VYJUVEK.

## SEC filing metadata
- accession: 0001711279-23-000067
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000067/0001711279-23-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000067/krys-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000067
- JSON: https://secwatch.observer/filing/0001711279-23-000067.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000067.txt

## Key facts
- Earnings Releases
  Krystal Biotech, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 7, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000067/0001711279-23-000067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.